Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P2X3 antagonist (Guangzhou Nanxin Pharmaceutical)
- Development stage
- Preclinical
- Lead developer
- Guangzhou Nanxin Pharmaceutical
- Modality
- Small Molecules
01
Overview
The P2X3 antagonist being developed by Guangzhou Nanxin Pharmaceutical (also known as Nucien) is a small molecule drug candidate targeting the P2X3 receptor for the treatment of chronic cough, including refractory and unexplained chronic cough (RCC/UCC). P2X3 receptors are ATP-gated ion channels located on the sensory vagal fibers (C-fibers) in the airways. In patients with chronic cough, these receptors are thought to be hypersensitized by ATP released during airway inflammation or irritation, leading to an excessive cough reflex. By acting as an antagonist, this molecule blocks the activation of P2X3 receptors, thereby reducing the hypersensitivity of the cough reflex and decreasing cough frequency. The program is currently in the preclinical stage of development.
- Other names
- P2X3拮抗剂
02
Targets
P2X3 (P2X purinoceptor 3)
Beyond the preview
Go deeper on P2X3 antagonist (Guangzhou Nanxin Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P2X3 antagonist (Guangzhou Nanxin Pharmaceutical).